On Oct 09, major Wall Street analysts update their ratings for $MBX Biosciences (MBX.US)$, with price targets ranging from $30 to $44.
J.P. Morgan analyst Jessica Fye initiates coverage with a buy rating, and sets the target price at $30.
Jefferies analyst Michael Yee initiates coverage with a buy rating, and sets the target price at $35.
Guggenheim analyst Seamus Fernandez initiates coverage with a buy rating, and sets the target price at $44.
Stifel analyst Annabel Samimy initiates coverage with a buy rating, and sets the target price at $40.
Furthermore, according to the comprehensive report, the opinions of $MBX Biosciences (MBX.US)$'s main analysts recently are as follows:
MBX Biosciences is advancing its research in the area of peptide-based therapies, focusing on well-established targets within the endocrine/metabolic sector, utilizing its exclusive Precision platform designed to enhance drug profiles. The company's primary candidate, MBX 2109, is seen as a significant initial endeavor into treating chronic hypoparathyroidism, with a Phase II trial currently underway and anticipated results due in the third quarter of 2025. The upcoming year is expected to provide several key milestones and potential value-adding events for MBX's diverse developmental pipeline.
MBX Biosciences is seen to have a promising outlook, with its MBX-2109 treatment in Phase II showing a high likelihood of positive results for parathyroid hormone conditions. The company's robust peptide platform is recognized for its potential to increase the duration and enhance the effectiveness of peptide therapies in the realms of PTH and obesity. Additionally, the current valuation of the company's shares is considered attractive.
The initiation of coverage on MBX Biosciences reflects recognition of its potent and efficient technology platform, which is focused on developing precision endocrine peptides for rare endocrine and metabolic disorders. These disorders present significant market opportunities. MBX Biosciences has fine-tuned pharmaceutical attributes to enhance therapeutic applications—maintaining peptide stability, minimizing variability, prolonging action, and crucially, lessening the necessity for frequent injections.
The potential shown by MBX Biosciences' extended-duration peptides aimed at clinically de-risked targets within specialized endocrine and wider metabolic diseases has been acknowledged. The key focus is on MBX 2109, a pioneering once-weekly peptide that addresses a market opportunity valued at over $7 billion, specifically for post-bariatric hypoglycemia.
Here are the latest investment ratings and price targets for $MBX Biosciences (MBX.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月9日，多家华尔街大行更新了$MBX Biosciences (MBX.US)$的评级，目标价介于30美元至44美元。
摩根大通分析师Jessica Fye首予买入评级，目标价30美元。
富瑞集团分析师Michael Yee首予买入评级，目标价35美元。
Guggenheim分析师Seamus Fernandez首予买入评级，目标价44美元。
斯迪富分析师Annabel Samimy首予买入评级，目标价40美元。
此外，综合报道，$MBX Biosciences (MBX.US)$近期主要分析师观点如下：
MBX生物科学正在推进其在肽基疗法领域的研究，专注于内分泌/代谢板块中成熟的靶点，利用其独有的Precision平台来优化药物属性。该公司的主要候选药物MBX 2109被视为治疗慢性甲状旁腺功能减退症的重要初步尝试，目前正在进行第二期试验，预计将在2025年第三季度公布结果。未来一年预计将为MBX的多样化发展管线提供几个关键里程碑和增值事件。
MBX生物科学被认为具有乐观的前景，其处于第二期的MBX-2109治疗显示出在甲状旁腺激素状况方面取得积极结果的高可能性。该公司强大的肽平台以其提高肽治疗在PTH和肥胖领域的持续时间和有效性的潜力而闻名。此外，该公司股票的当前估值被认为具有吸引力。
对MBX生物科学的覆盖启动反映了对其强大而高效的科技平台的认可，该平台专注于为罕见内分泌和代谢紊乱开发精确的内分泌肽。这些紊乱带来了重要的市场机遇。MBX生物科学已经优化了药品属性，以增强治疗应用，保持肽稳定性，减少可变性，延长作用时间，并且关键的是减少了频繁注射的需要。
MBX生物科学展示的针对临床风险降低目标的延长时间肽显示出潜力，涉及专门的内分泌和更广泛的代谢疾病。重点放在MBX 2109上，这是一种开创性的每周一次的肽，针对一个价值超过70亿美元的市场机会，特别是用于术后低血糖。
以下为今日4位分析师对$MBX Biosciences (MBX.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
